Five-year strategic material agreement delivers critical defense materials through 2030 DALLAS, June 11, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced a new long-term strategic material supply agreement with BWX Technologies, Inc. (NYSE: BWXT), strengthening the decades-long partnership supporting the U.S. Naval Nuclear Propulsion Program. The agreement runs through fiscal year 2030.

ATI Engage® Series, a product by ATI Nursing Education, is the winner of the Digital Learning Innovation Award in the 8th annual EdTech Breakthrough Awards

Seasoned investor relations and finance leader succeeds retiring David Weston DALLAS, June 8, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced that Rob Rengel has been named Vice President of Investor Relations, effective June 22, 2026. Rengel succeeds David Weston, who is retiring effective July 3, 2026, after helping strengthen ATI's engagement with the investment community during a period of significant transformation and growth.

DALLAS, June 3, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced today that it has priced its public offering of senior notes. ATI has agreed to sell $450 million aggregate principal amount of 5.875% Senior Notes due 2033 (the "Notes").

DALLAS, June 3, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced today its intention to offer, subject to market and other conditions, a series of seven-year senior notes (the "Notes").  ATI intends to use the net proceeds of the offering of the Notes to redeem all of its outstanding 5.875% Senior Notes due 2027 (the "2027 Notes").

DALLAS, May 18, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) Kimberly A. Fields, ATI Board Chair, President and Chief Executive Officer will speak at the Bernstein 42nd Annual Strategic Decisions Conference on May 28, 2026, at 3:30 p.m.

Leroy Ball named Lead Independent Director DALLAS, May 14, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced that at the conclusion of its 2026 Annual Meeting today, Kimberly A. Fields became Board Chair in addition to her role as Chief Executive Officer and President.

Margin expansion and aerospace demand drive double-digit earnings growth GAAP EPS up 27% year-over-year; Operating cash flow up $221 million Adjusted EBITDA margin 20.1%, up 310 bps. year-over-year Raising full year adjusted earnings and cash flow guidance    First Quarter 2026 GAAP Financial Results Sales of $1.15 billion, up 1% year-over-year, driven by a 6% aerospace & defense increase Net income attributable to ATI of $118 million, up 22% year-over-year Earnings per share of $0.85 compared to $0.67 per share in first quarter 2025 First Quarter 2026 Non-GAAP Financial Information (a) Adjusted net income attributable to ATI(a) of $139 million, up 33% year-over-year Adjusted earnings per share(a) of $1.00, compared to $0.72 per share in first quarter 2025 Adjusted EBITDA(a) of $232 million, an increase of 19% year-over-year Adjusted EBITDA(a) as a percentage of sales of 20.1%, compared to 17.0% in first quarter 2025 Guidance The Company is providing second quarter and updated, full year 2026 guidance in the table below.

- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -  - Estimated Half-Life of Approximately 45 Days; Unlocks Opportunity for up to Three-Month Dosing Interval - - Complete and Sustained Inhibition of TSLP-Induced and IL-4 Induced CCL17 (TARC) Provides Potential to Raise Efficacy Ceiling in Th2-Driven Diseases - - Enrollment and Dosing Ongoing in Phase 1b Trials in Asthma and Atopic Dermatitis (AD) with Top Line Results Expected in the Second Half of 2026 - - Lichen Planus Selected as Lead Indication for ATI-2138; Potential to be First Mechanistically Complete Therapeutic Candidate Designed to Address Root Inflammation and Symptoms - - Management to Host a Conference Call to Discuss Update Today at 8:30 AM EST - WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided a clinical update on its biologic and oral inhibitor compounds including positive full top line results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 and the selection of lichen planus (LP) as the lead indication for its selective ITK/JAK3 inhibitor ATI-2138.